Delamanid for Multidrug-Resistant Pulmonary Tuberculosis

In this report on the treatment of multidrug-resistant (MDR) tuberculosis, the authors found that delamanid, a novel anti-TB medication, led to more rapid sputum culture conversion to negative when added to a background regimen than the background regimen alone. The emergence over the past two decad...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2012-06, Vol.366 (23), p.2151-2160
Hauptverfasser:	Gler, Maria Tarcela, Skripconoka, Vija, Sanchez-Garavito, Epifanio, Xiao, Heping, Cabrera-Rivero, Jose L, Vargas-Vasquez, Dante E, Gao, Mengqiu, Awad, Mohamed, Park, Seung-Kyu, Shim, Tae Sun, Suh, Gee Young, Danilovits, Manfred, Ogata, Hideo, Kurve, Anu, Chang, Joon, Suzuki, Katsuhiro, Tupasi, Thelma, Koh, Won-Jung, Seaworth, Barbara, Geiter, Lawrence J, Wells, Charles D
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Antitubercular Agents - adverse effects Antitubercular Agents - pharmacokinetics Antitubercular Agents - therapeutic use Clinical trials Double-Blind Method Drug dosages Drug resistance EKG Female HIV Human immunodeficiency virus Humans Male Middle Aged Mortality Multidrug resistance Multidrug resistant organisms Mycobacterium tuberculosis - growth & development Mycobacterium tuberculosis - isolation & purification Nitroimidazoles - adverse effects Nitroimidazoles - pharmacokinetics Nitroimidazoles - therapeutic use Oxazoles - adverse effects Oxazoles - pharmacokinetics Oxazoles - therapeutic use Patients Sputum Sputum - microbiology Survival Analysis Tuberculosis Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - microbiology Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!